Replies to post #163899 on Biotech Values

[oc631]

It is precisely these reasons you cite, namely the fact that GILD has a lot to recoup from the VRUS purchase, that leads me to believe that the competition will be able to carve out a nice niche competing on price.

Great point and the true value driver for simeprevir in emerging markets.

[DewDiligence]

GILD—According to @AndyBiotech on Twitter (a reliable source), the new GT1/GT3 trial is intended for approval in Russia only.